58 related articles for article (PubMed ID: 19255987)
21. The role of recombinant erythropoietin in childhood cancer.
Shankar AG
Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human erythropoietin in the treatment of nonrenal anemia.
Heuser M; Ganser A
Ann Hematol; 2006 Feb; 85(2):69-78. PubMed ID: 16078035
[TBL] [Abstract][Full Text] [Related]
23. [Anemia in lung cancer patients].
Méric JB; Morère JF;
Bull Cancer; 2005 May; 92(5):439-44. PubMed ID: 15932807
[TBL] [Abstract][Full Text] [Related]
24. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.
Sheffield R; Sullivan SD; Saltiel E; Nishimura L
Ann Pharmacother; 1997 Jan; 31(1):15-22. PubMed ID: 8997459
[TBL] [Abstract][Full Text] [Related]
25. Alfa-epoietin and anaemia in gynaecological cancer.
Di Cocco B; Salesi N; Fabi A; Nardoni C; Ferretti G; Bossone G; Ciccarese M; Savarese A; Vecchione A; Cognetti F
Anticancer Res; 2004; 24(2C):1287-92. PubMed ID: 15154662
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease.
Oba Y
Am J Manag Care; 2009 Feb; 15(2):97-104. PubMed ID: 19284806
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?
Osterborg A
Med Oncol; 1998 Aug; 15 Suppl 1():S47-9. PubMed ID: 9785337
[No Abstract] [Full Text] [Related]
28. [Anemia and chemotherapy].
Ray-Coquard I; Bachelot T; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2003 Apr; 90 Spec No():S133-43. PubMed ID: 12856425
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
Spano JP; Khayat D
Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
[TBL] [Abstract][Full Text] [Related]
30. EPO in cancer anemia: benefits and potential risks.
Milano M; Schneider M
Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
[TBL] [Abstract][Full Text] [Related]
31. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
Spaëth D
Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
[TBL] [Abstract][Full Text] [Related]
32. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
Beutel G; Ganser A
Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
[TBL] [Abstract][Full Text] [Related]
33. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
[TBL] [Abstract][Full Text] [Related]
35. [Indications and limits of recombinant human erythropoietin in intensive care unit].
Ventré C; Rousseau S; Albanèse J; Leone M; Martin C
Ann Fr Anesth Reanim; 2004 Jul; 23(7):714-21. PubMed ID: 15324960
[TBL] [Abstract][Full Text] [Related]
36. The ASH/ASCO clinical guidelines on the use of erythropoietin.
Lichtin A
Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
Cremieux PY; Finkelstein SN; Berndt ER; Crawford J; Slavin MB
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):459-72. PubMed ID: 10662393
[TBL] [Abstract][Full Text] [Related]
38. EPO's alter ego: erythropoietin has multiple actions.
Lappin TR; Maxwell AP; Johnston PG
Stem Cells; 2002; 20(6):485-92. PubMed ID: 12456956
[TBL] [Abstract][Full Text] [Related]
39. [Human recombinant erythropoietin therapy].
Donato H; Ferro H
Medicina (B Aires); 2006; 66(1):51-69. PubMed ID: 16555732
[TBL] [Abstract][Full Text] [Related]
40. Developments in the therapeutic use of erythropoiesis stimulating agents.
Jelkmann W
Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
